T. Rowe Price Associates’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $149K | Hold |
|
|||||
|
2025
Q2 | $100K | Buy |
|
|||||
|
2025
Q1 | $52K | Buy |
|
|||||
|
2024
Q4 | $58K | Hold |
|
|||||
|
2024
Q3 | $91K | Buy |
|
|||||
|
2024
Q2 | $0 | Buy |
|
|||||
|
2023
Q3 | – | Sell |
|
|||||
|
2023
Q2 | $2.63M | Sell |
|
|||||
|
2023
Q1 | $2.55M | Sell |
|
|||||
|
2022
Q4 | $5.71M | Buy |
|
|||||
|
2022
Q3 | $5.74M | Sell |
|
|||||
|
2022
Q2 | $15.6M | Sell |
|
|||||
|
2022
Q1 | $36.2M | Sell |
|
|||||
|
2021
Q4 | $57.6M | Buy |
|
|||||
|
2021
Q3 | $76.8M | Buy |
|
|||||
|
2021
Q2 | $64.8M | Sell |
|
|||||
|
2021
Q1 | $67M | Buy |
|
|||||
|
2020
Q4 | $62.9M | Buy |
|
|||||
|
2020
Q3 | $23.7M | Buy |
|
|||||
|
2020
Q2 | $27.7M | Buy |
|